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Introduction
Malaria is still one of the world’s biggest killers. Why, 105 years
after Ross discovered the way malaria was transmitted via the
mosquito vector and a century after he received the Nobel prize
for this seminal discovery, is malaria still such a big problem?
This is undoubtedly in part due to the lack of resources that have
been devoted to solving this problem at a scientific and practical
implementation level.
Malaria eradication was suggested in the 1960s, when indoor
residual spraying with DDT and chloroquine prophylaxis was a
powerful combination for reducing malaria transmission (see
Box 1). On the fringes of malaria transmission in Europe and in
parts of South-East Asia, this campaign was a spectacular
success, but in the African and Asian malaria heartlands it soon
became clear that eradication with available tools, expertise,
manpower and funding was impractical. Resistance in the
parasites to the available drugs and in the mosquito vectors to
DDT also reduced the efficacy of the available tools, and the
euphoria of proposed eradication gave way to efforts to institute
sustainable control of malaria.
The poverty of the countries where malaria transmission is
most intense and where donors are unwilling to underpin
open-ended disease control programmes, mean that it is crucial
to allocate resources for malaria control to clearly defined priorities
that are based on established evidence. Good leadership and
political will are essential to implement evidence-based malaria
control interventions on a national scale, but are often lacking.
In Abuja, Nigeria, in 2000, delegations from 44 African nations
met in the largest ever heads-of-state summit focused on a single
health issue. They pledged to take decisive steps towards
halving the world’s malaria burden by 2010, and to ensure that
60% of those affected have access to treatment, protection
during pregnancy, and sleep under insecticide-treated nets
(ITNs). These promises were made as the African leaders signed
up to ‘Roll Back Malaria’ (RBM), a global partnership created in
1998 by the World Health Organization, the United Nations
Development Programme, the United Nations Children’s Fund
and the World Bank. Despite such initiatives, there is little sign of
delivery or adequate progress towards the Abuja goals.
Major breakthroughs are now expected with the availability of
the genome sequence of a number of human pathogens and
their insect vectors. Since the publication of the whole genome
sequence of Haemophilus influenzae in 1995, there has been a
deluge of information based on sequencing pathogen genomes,
including the recent release of the Plasmodium falciparum and
Anopheles gambiae sequences. The rapid rise in the number of
genomes sequenced has resulted from developments in both
molecular and computational sciences, and from a realization of
the impact of genome information on studying the biology of
organisms. New opportunities to examine global changes in
transcription and translation have also been derived from these
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The genomes of the malaria parasite Plasmodium falciparum and a
major vector, Anopheles gambiae, have now been sequenced. The
former is in a finished format while the latter still requires complete
closure and annotation. The challenge now is to use this major
resource, which is freely searchable by all scientists, to develop
new effective control methods for diseases such as malaria. Once
these methods have been developed, a further large challenge
is their operational implementation, given the lack of success
internationally of achieving the Abuja targets with impregnated
bednets for malaria.
Box 1. Malaria — the disease
Malaria in humans is caused by the transmission of sporozoites from
infected anopheline mosquitoes during feeding. The complex life cycle (see
Fig. 1) results in the multiplication of parasites in the bloodstream following a
48-hour (for P. falciparum) cycle of invasion, replication and release. It is
after the rupture of the infected red blood cells that the characteristic spike in
fever is seen.
Mortality from P. falciparum malaria has been variably estimated at between
1 and 2 million deaths per year (mainly in children under five in sub-Saharan
Africa), making it one of the big three infectious diseases in developing
countries, the other two being tuberculosis and HIV/AIDS. In addition,
although difficult to estimate,26 the economic burden on the poorest countries
is also substantial. Despite an overall reduction in childhood mortality in
Africa over the last few decades,27 the proportion of deaths attributable to
malaria may have risen, due to increasing drug resistance and lack of
effective vector control programmes.
Fig. 1. The stages in the life cycle of the anopheline mosquito. Source: World
Health Organization.
studies, enabling a different type of approach to be added to the
scientific armoury.
Despite the technological advances, sequencing a relatively
small parasite or mosquito genome is not a trivial matter. Infor-
mation is released either as a ‘draft’ or ‘finished’ sequence. Both
are based on sequencing many random segments of the genome
and using computers to assemble these pieces into the whole
sequence. This phase is fast and produces a large amount of
information, in a ‘draft’ format, about the genes present in a
particular organism.
However, random sequencing leaves gaps in the sequence due
to under-representation of segments in sequence libraries and
difficulties in sequencing or assembling certain regions. Filling
gaps is a major task and, unlike the highly automated random
sequencing phase, requires input from skilled staff to identify
and sequence these gaps. Having the ‘finished’ sequence of a
genome allows a full picture of the genetic make-up of an
organism to be developed, but at a cost.
Nevertheless, the release of a ‘draft’ sequence can make a
substantial contribution to the research community. The
P. falciparum genome sequence is ‘finished’ but ‘draft’ sequences
have been available on the Web since the start of the project,
providing investigators with valuable information. The
A. gambiae sequence is in ‘draft’ form and will still take several
years to finish, but is available in a robust searchable format.
Plasmodium falciparum genome information
The nuclear genome of Plasmodium falciparum parasite 3D7 is
22.8 mega-base pairs (Mb) (mitochondrial and apicoplast
genomes are 6 and 35 kb, respectively). Of the 5268 genes
predicted by various algorithms, half have introns. As well as
genes coding for proteins, the nuclear genome contains 43 trans-
fer RNAs (tRNAs), showing low redundancy. The mitochondrial
genome has no tRNAs, whereas the apicoplast genome encodes
enough tRNAs for local protein synthesis. The ribosomal RNA
(rRNA) genes are relatively few in number and are spread
throughout the genome, unlike the clustered organization
found in other organisms. The developmental regulation of
rRNA expression, divided into asexual (human host) and sexual
(mosquito) stages, may relate to this organizational difference.
No identifiable retrotransposons or transposable elements were
found.
The fourteen chromosomes vary from 0.643 to 3.29 Mb in
length and potential centromere regions have been identified
for most chromosomes. The subtelomeric regions of all the
chromosomes were highly similar, divided into five blocks of
conserved tandem repeats or non-repeat regions. The highly
variable multigene families var, rif and stevor are contained
within the fourth block from the telomere. Strikingly, 60% of the
P. falciparum predicted proteins are listed as ‘hypothetical’, with
no homology to any sequenced functional protein to date. These
proteins are apparently unique to Plasmodium (by comparison,
approximately 50% of proteins in Anopheles share some
homology with Drosophila proteins). This may reflect the evolu-
tionary distance of Plasmodium from other available sequenced
organisms, but it may also reflect a true difference in the biology
of this organism.
Of the 40% of proteins with an assigned function,1 P. falciparum
has a much higher percentage of proteins involved in cell
adhesion and invasion than Saccharomyces cerevisiae, as expected
from the former ’s parasitic life cycle. The categories ‘cell
organization’, ‘cell cycle’ and ‘transcription factors’ were
reduced relative to S. cerevisiae but the lack of predicted proteins
identified in these classes does not mean that these functions do
not exist in P. falciparum.
Subtelomeric regions of the chromosomes contain several
multigene families. Var genes (59 copies in 3D7) encode
P. falciparum erythrocyte membrane protein 1, PfEMP1, a family
of proteins involved in both host immune evasion and
pathogenesis of malaria during the disease-causing asexual
intra-erythrocytic stages. Rifins (repetitive interspersed family;
encoded by 149 rif gene copies) have also been demonstrated on
the surface of asexual-stage infected red blood cells, but 3D7 has
relatively low rif expression.2 3D7 was chosen for the sequencing
project because it can make gametocytes in vitro, whereas
other P. falciparum lines cannot, particularly those established in
laboratory culture for some time. Proteomic studies revealed
groups of genes with coordinated regulation, some of which
form clusters within the genome. Investigation of the non-
coding regions associated with coordinately expressed genes
may reveal regulatory sequences.
Comparative genomics
The provision of a ‘finished’ sequence for the P. falciparum
genome provides a framework for related Plasmodium species
genomes to be modelled on. Information from ‘draft’ sequencing
of other Plasmodium species has also facilitated gene discovery in
P. falciparum. The status of genome sequencing in all malaria
species was reported recently.3 Synteny, the conserved organiza-
tion of similar genes within a chromosomal context in different
species, occurs especially within species of rodent malaria para-
sites4 and within the four species of human malaria parasites.5
Extensive synteny facilitates assembly of sequences and identifi-
cation of genes, and demonstrates evolutionary relationships.5,6
Predicted proteins from the genomes of rodent parasites
P. yoelii yoelii and P. chabaudi (a partial set from a genome survey
sequencing project) were compared with those of P. falciparum.
In 5878 P. y. yoelii genes7 and in 766 P. chabaudi genes,8 roughly half
were similar to P. falciparum predicted proteins. Identification of
orthologues in biochemical pathways supports the use of rodent
models to investigate mechanisms of drug activity. Additionally,
discovering parallel pathways in other Apicomplexan parasites
more amenable to experimentation, such as Toxoplasma gondii,
may lead to a better understanding of Plasmodium species.
Therapeutics
An integrated map of metabolic pathways and of transporters
allows researchers to identify properties unique to the parasite.
Examples of recently identified drug targets with orthologues in
P. y. yoelii7 include the apicoplast-specific enzymes, 1-deoxy-D-
xylulose 5-phosphate reductoisomerase (DOXPR), inhibited by
fosmidomycin (in clinical trials9) and enoyl-acyl carrier protein
(ACP) reductase (FabI), inhibited by triclosan.10 Genome infor-
mation can also highlight potential difficulties, such as multiple
proteins involved in specific pathways, and also contribute to
the resolution of these problems (e.g. plasmepsins). The chal-
lenge now will be to use the genome information to ask the
‘right’ questions, efficiently, to optimize our understanding of
this parasite and its interactions with the mosquito vector and
human host, and to develop novel therapeutics or even novel
vaccine candidates/strategies.
Anopheles gambiae genome information
The sequence of the nuclear genome of the PEST strain of
A. gambiae consists of 278 Mb DNA11 (the mitochondrial genome
is 15.3 kb and contains 27 genes).12 The sequence is currently in
draft form; gaps and regions of potential misassembly are
highlighted within the sequence, most notably on the largely
non-coding, highly repetitive Y-chromosome. Yet despite this,
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the immediate opportunities to develop urgently required novel
methods of mosquito control afforded by this genome data-set
fully justifies the publication of the genome in its draft format.
The PEST strain of A. gambiae is a hybrid strain derived from
crossing a laboratory colony of Nigerian origin with the
offspring of wild mosquitoes from Kenya.13 This strain was
chosen, in part, because it lacked the large-scale chromosomal
rearrangements that are typical of many A. gambiae populations.
During genome assembly, however, it became apparent that this
strain possessed an unexpected amount of heterogeneity, posing
problems for the assemblers, but at the same time providing a
rich depository of single nucleotide polymorphisms (SNPs) that
will be extremely valuable for population studies.11 At 278 Mb,
the A. gambiae genome is considerably larger than the 122 Mb
assembled sequence of Drosophila melanogaster,14 but smaller than
the predicted size of many other mosquito disease vectors.15 The
difference in size between A. gambiae and D. melanogaster is
largely due to intergenic DNA. Automatic annotation programs
predicted a similar number of genes in both species (13 683 genes
in A. gambiae versus 13 379 in D. melanogaster11,16 ).
Current malaria programmes cover both malaria prevention
and treatment. Prevention of disease transmission is accomplished
through control of the insect vectors at the population level and
use of insecticide-impregnated nets and other materials to
prevent mosquito biting, at the individual and household level.
Malaria drug prophylaxis can be used to provide additional
protection against malaria for groups at particular risk such as
pregnant women living in, and travellers to, endemic countries.
Successful operational implementation of each of these
malaria prevention strategies is subject to constraints, with
problems building faster in some areas than others. For example,
a central plank of RBM strategy is operational, large-scale use of
ITNs. The only insecticide class that can currently be used on
nets are the pyrethroids. In 1998, when large-scale ITN use was
proposed, it was assumed that the major African vectors
(A. gambiae and A. funestus) were fully susceptible to these
insecticides. Since then, resistance networks, established
through the Multilateral Initiative on Malaria (MIM) scheme,
have demonstrated that serious resistance problems are present
in both vectors. A. gambiae throughout much of West Africa has
a high frequency of target site resistance (knockdown resistance,
or kdr) while A. funestus has a metabolic mechanism, which
produces high-level resistance to pyrethroids. We may have
been lucky with A. gambiae, as the kdr mechanism is functionally
recessive and the behaviour change it produces in the homozy-
gous kdr mosquitoes result in only minor changes in ITN
efficacy for reduction of malaria transmission.
The situation in southern African is more worrying because
resistance of A. funestus has compromised the use of pyrethroids
for both residual spraying and ITNs. An obvious fear is that this
metabolic pyrethroid resistance mechanism will eventually be
selected in A. gambiae and there is now evidence of this in parts of
West Africa and in Kenya.
Effective management of insecticide resistance requires
detailed knowledge of the mechanisms involved. The develop-
ment of PCR-based assays for one of the main insecticide resis-
tance mechanisms, kdr, has enabled resistant alleles to be
detected at very low frequencies and has facilitated population-
based studies to assess their impact on net efficacy.17 But kdr
is only one of several potential resistance mechanisms. An
inventory of the three major enzyme families associated with
metabolic resistance to insecticides has identified nearly 200
genes encoding glutathione transferases, cytochrome P450s or
carboxylesterases.18 The challenge now is to determine the
specific members of these supergene families that are involved
in insecticide detoxification. This task will be facilitated by the
integration of the genome sequence information with genetic
mapping data, which has already broadly defined the boundaries
within which many of the major loci associated with metabolic
resistance lie.18
The search for novel insecticidal targets will clearly be facili-
tated by the genome data-set. Thirty-five genes encoding
regulatory peptides governing key physiological pathways in
the mosquito have already been described.19 Interfering with
one or more of these pathways may give rise to effective future
mosquito control strategies. The genome sequence availability
may also allow us to develop novel synergists or ‘resistance-
breakers’ rapidly to restore the efficacy of the pyrethroids and
other insecticides. Targeting such molecules against the
insect-specific regulators of the metabolic resistance mechanism
should avoid the problems of increased human toxicity common
to currently available synergists. Development and registration
of such molecules, if they have little or no mammalian toxicity,
should also be relatively rapid.
A. gambiae was selected for full genome sequencing from the 60
or so anopheline mosquito species that transmit malaria largely
because of the vast number of deaths attributed to bites from this
mosquito. It belongs to a group of sibling species known as the
A. gambiae complex that differ in their ecology and ability to
transmit disease. The efficiency of A. gambiae sensu stricto as a
vector of malaria is due to its remarkable adaptation to living in
close association with humans and its extreme preference for
feeding on human blood. What is it about humans that this
mosquito species finds so attractive? The identification of 79
A. gambiae genes encoding putative odorant receptors20 may
help answer this question. If, as predicted, members of this
supergene family recognize chemical signals exuded exclusively
by humans, a new generation of attractants or repellents acting
as decoys to these odorant receptors may prove effective in
reducing human malaria transmission.
Genetic engineering
The application of genetic engineering to mosquito control has
received much attention recently, and the availability of the
A. gambiae genome sequence will undoubtedly accelerate the
development of laboratory strains that are unable to transmit
pathogens. A description of the 242 A. gambiae genes implicated
in innate immunity responses accompanied the genome release,
and this will facilitate delineation of the mosquitoes’ response
to pathogens,21 whereas analysis of global changes in gene
expression following blood meal or infection will assist the
search for additional effector molecules.11 Further studies of the
40 different classes of transposable elements present in the
mosquito genome11 may identify improved means of driving
parasite-resistant genes through natural populations. While this
is all good news for the development of transgenic mosquito
populations in the laboratory, the biggest challenges to the
success of this strategy will manifest themselves during field
trials. The challenge to proponents of this scheme is to use the
genome sequence to complement field studies of disease trans-
mission ecology.
Other potential uses of modern genomic and transgenic
technology may provide novel solutions to malaria control in the
longer term. Not all mosquito species are able to transmit the
malaria parasite. The genes that encode this refractory pheno-
type are now being characterized. These genes, or single-chain
variant fragment antibodies against the parasite, could be stably
inserted into the genomes of major vectors to block transmission.
While such transgenic technology was close to science fiction a
decade ago, we now have all the available technology to
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produce refractory mosquitoes and proof of principle in both
A. gambiae and Aedes aegypti (the latter with bird malaria) that the
technology will work. The major hurdles in introducing this
new technology are to develop methods of rapid mosquito field
population replacement and to gain acceptance of the technology
by the human population living in the regions where malaria is
endemic.
Web-based resources
The entire genome assembly of Anopheles is available through
Genbank or in CD-ROM format (freely available from Science).
Both the Genbank and Ensembl sites can be used to search for
particular sequences of interest, either by gene name or by
BLAST searching a particular sequence, although the caveats
outlined above for the parasite genome annotation should be
noted. Manual inspection and ultimately experimental verifica-
tion are needed to confirm or rectify many of the automated
annotations.
Several large-scale A. gambiae EST sequencing projects have
been completed that could assist in this process. A useful
resource that amalgamates cDNA sequence data from various
sources with information from automated annotation pipelines
can be found within The Institute for Genomic Research (TIGR)
web site (see Box 2). The data from the Malaria Genome
Sequencing Project is readily available to anyone with a com-
puter to ask questions about the parasite genome.
The Internet is the best way to access the data (see Box 2 for
details), but for those who are ‘out in the field’, many of the data
are available on the GenePlot CD (available from PlasmoDB).
Specific questions, such as ‘is my favourite protein expressed at a
particular stage of development?’ can be asked easily using a
simple BLAST or text search. There are a few considerations for
using the information. Much of the gene data is for predicted
proteins, some of which have homology to proteins with known
functions in other organisms. However, many of the ‘genes’ in
the database are ‘gene models’ based on computer algorithms
and so the functions of these proteins in the parasite, and even
the correctly spliced coding sequence, need to be verified experi-
mentally. Conversely, gene prediction algorithms may have
‘missed’ genes of interest, so it pays to follow up any ‘hits’, even if
a full gene does not come out of a search. Despite the large size of
the database, it is still not comprehensive, as the sequenced
genome represents only one of countless P. falciparum geno-
types, which differ from one another due to deletions and
duplications. Thus, the sequenced laboratory line 3D7 itself has
sequence and expression features that distinguish it from other
P. falciparum genotypes.
Comparative genomics
Comparative analysis of the mosquito proteome with that
of Drosophila reveals an unexpected amount of evolutionary
relatedness. Almost half of the genes in both Anopheles and
Drosophila have one clear orthologue in the other species. A
further 40% have good matches to proteins in Drosophila (32%)
or another species (8%) but are not necessarily orthologous.
Finally, only just over 10% of the putative Anopheles proteins
have no detectable similarity to proteins in any other sequenced
genome.22
This type of comparative analysis enables gene families
that are specific to, or absent from, insects to be identified,
information that will be valuable for the development of novel
classes of insecticides. In addition, the identification of classes of
proteins that are over-represented in the mosquito compared to
the fly may provide clues to the biochemical pathways involved
in seeking and processing blood meals.
If successful global mosquito control strategies are to be
developed, they must tackle other malaria vectors in addition to
A. gambiae. The ability to use the A. gambiae genome as a frame-
work to assemble partial genome sequence data obtained from
other anopheline mosquito species depends on the degree of
conservation of gene order (microsynteny) between different
species. A comparative genomic study between A. gambiae and
A. funestus, which occur sympatrically across much of sub-
Saharan Africa and are thought to have diverged approximately
5 million years ago, found extensive synteny at the level of
chromosome arms but widespread variation in local gene
order.23 Although problematic for the transfer of functional
genomics studies between species, further comparative studies
of these two genomes are likely to provide valuable insights into
the mechanism and effects of chromosomal inversions and
rearrangements within Anopheles species.23
Chromosomal inversions on chromosome 2R are widespread
within the A. gambiae complex and are believed to indicate adap-
tations to different environmental niches.24 Identification of
genes encoded within these inversions may provide clues to fac-
tors determining mosquito behaviour and vectorial capacity.25
After a decade or more of neglect and under-funding, malaria
is now firmly back on the political and health agendas. New
alliances and funding initiatives, such as RBM, the Global Fund
for HIV/AIDS, TB and Malaria, Medicines for Malaria, and the
Multi-lateral Initiative on Malaria, should provide the impetus
for striving to achieve the Abuja targets and support development
of new tools and techniques for malaria control and treatment.
These initiatives also provide a much-needed opportunity to
train the next generation of African malaria researchers,
technicians and operational control specialists, and should start
to redress the loss of capacity in this area, which has been
apparent in the last decade.
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Box 2. Web-based resources: web sites
PlasmoDB: the official database of the malaria parasite genome
project.
http://www.plasmodb.org/
National Institutes of Health malaria and mosquito genome project
information
http://www.ncbi.nlm.nih.gov/projects/Malaria/
http://www.ncbi.nlm.nih.gov/mapview/map_search.cgi?chr=agambiae.inf
Ensembl mosquito genome assembly and annotation
http://www.ensembl.org/Anopheles_gambiae/
The Institute of Genome Research gene index site
http://www.tigr.org/tdb/tgi/
MR4 site
http://www.malaria.mr4.org/index.html
South African National Bioinformatics Institute BLAST searcher
comparing P. falciparum, P. vivax and P. berghei GSS and EST
http://www.sanbi.ac.za/malaria-genesearch/
For general molecular biology of malaria parasites
http://www.wehi.edu.au/MalDB-www/who.html
For general information about Anopheles mosquitoes
http://www.anobase.org/
P. berghei information
http://www.lumc.nl/1040/research/malaria/genomics_proteomics.html
BLAST against many different parasite genomes
http://www.ebi.ac.uk/blast2/parasites.html
http://www.sanger.ac.uk/Projects/Protozoa/
GO: Gene Ontology database: controlled vocabulary for genes and
functions in all sequenced organisms.
http://www.geneontology.org/
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Human immunodeficiency virus — one of nature’s
greatest evolutionary machines
Darren Martin and Carolyn Williamson*
From a human perspective, the human immunodeficiency virus
(HIV) story begins around 1930, somewhere in equatorial West
Africa, when it is thought that an obscure chimpanzee virus in-
fected a person.1–3 Unnoticed over the next fifty or so years, this
virus’s descendants spread among people throughout the
world. Even after HIV was discovered in the 1980s, its spread
was relentless, despite intense efforts to stop it. Understanding
this story, and learning from it, is one of the most difficult and
important endeavours that humankind has yet undertaken.
HIV’s ancestors
Long before the first HIV infection of humans, biological
evolution had already produced in HIV’s ancestors the mixture
of features that has made the global AIDS pandemic possible.
These viruses had the potential to evade our defences, integrate
into our genomes, reproduce in our cells and not kill us before
exploiting our sexual habits to move between us.
HIV-like viruses have been discovered in more than twenty
African primate species belonging to two families (apes and
monkeys). Transmission of HIV-like viruses between different
primate species has most likely occurred for many centuries.4
With few exceptions, the HIV-like infections found in their natu-
ral primate hosts are not obviously pathogenic. A degree of toler-
ance (that is, susceptibility without death) may have developed
in, for example, chimpanzees if the virus was introduced from a
different ape species, spread unabated through the chimpanzee
population and killed all susceptible individuals. The small
fraction of chimpanzees that survived infection without devel-
oping an AIDS-like disease would produce offspring that were
themselves tolerant and, in only a few hundred years, infections
would no longer be terminal.
If frequent transmission of HIV-like viruses has occurred
between the different primate species, a reasonable question to
ask is: Why have HIV-like viruses not been transmitted into
humans before? It has, in fact, been determined that besides the
chimpanzee-to-human transmission incident supposedly
around 1930, there have been multiple transmissions of other
HIV-like viruses from primates to humans, resulting in two HIV
types (HIV-1 and -2) and three HIV-1 groups (HIV-1 group M,
group N, and group O).1,3,5 The HIV-1 group M viruses are
responsible for the worldwide AIDS pandemic. Although the
group N and O viruses have much in common with the group M
viruses, they are either not as deadly or have, for some reason,
not spread as successfully.
The virus and its life cycle
Virus particles, otherwise known as virions, are so small they
can be visualized only using electron microscopes. Virions are
Transmission of an HIV-like virus from chimpanzees to humans
approximately 80 years ago triggered the worldwide AIDS pan-
demic. Possessing very high mutation and recombination rates, the
descendants of this ancestral virus have evolved greatly. Most of
this evolution has been in response to selective pressures imposed
by human immune responses and has not provided HIV with any
significant new biological characteristics. The continuing diversifi-
cation of HIV variants is a principal obstruction to controlling the
virus with drugs and vaccines.
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